Pfizer-BioNTech COVID-19 Vaccine Safe, Effective in Cancer Patients
Pronounced lag in antibody production after the first dose found versus noncancer controls
COVID19 Vaccine
CDC Advisers to Discuss Third COVID-19 Vaccine Dose for Immunocompromised
Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its 2-dose vaccine
Q&A: Monoclonal Antibodies for COVID-19
The IDSA recommends that antibody therapy should be administered to patients with mild to moderate COVID-19 at high risk for progression to severe disease.
ACIP: Benefits of mRNA COVID-19 Vaccines Outweigh Risks for ≥12s
After reviewing evidence, including data on risks for myocarditis, vaccination benefits outweigh risks for all populations
Many Young Cancer Survivors Report COVID-19 Vaccine Hesitancy
37.1% of adolescent and young adult cancer survivors report vaccine hesitancy; higher odds of hesitancy for females
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Myocarditis-Like Illness Reported After COVID-19 Vaccination
Case series describes 7 cases in males younger than 40 years; all patients’ symptoms were resolved by the time of hospital discharge
COVID-19 Vaccines Do Not Interfere With Male Fertility
No significant decreases seen in any sperm parameters following 2 doses of an mRNA COVID-19 vaccine
Second COVID-19 Vaccine Dose Missed by More Than 10 Percent of Americans
Adults younger than 30 most likely to have missed second dose, with nearly 12 percent outside of the 42-day allowable window
Disparities in COVID-19 Vaccination ID’d Among Health Employees
At MetroHealth System, probability of vaccination up for employees older than 44 years, men, Whites, and Asians
- Loading...
Loading...
Next post in Practice Management
Loading... 
Loading...